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a b s t r a c t
Live-attenuated inﬂuenza virus (LAIV) vaccines may provide cross-protection against contemporary
inﬂuenza A virus (IAV) in swine. Conversely, whole inactivated virus (WIV) vaccines have the potential
risk of vaccine-associated enhanced respiratory disease (VAERD) when challenged with IAV of
substantial antigenic drift. A temperature sensitive, intranasal H1N2 LAIV was compared to wild type
exposure (WT) and an intramuscular WIV vaccine in a model shown to induce VAERD. WIV vaccinated
swine challenged with pandemic A/H1N1 (H1N1pdm09) were not protected from infection and
demonstrated severe respiratory disease consistent with VAERD. Lung lesions were mild and challenge
virus was not detected in the respiratory tract of LAIV vaccinates. High levels of post-vaccination IgG
serum antibodies targeting the H1N1pdm09 HA2 stalk domain were exclusively detected in the WIV
group and associated with increased H1N1pdm09 virus infectivity in MDCK cells. In contrast, infection-
enhancing antibodies were not detected in the serum of LAIV vaccinates and VAERD was not observed.
Published by Elsevier Inc.
Introduction
Contemporary inﬂuenza A viruses (IAV) circulating in North
American swine are characterized by extensive genetic and anti-
genic diversity that has increased since the introduction of the
triple reassortant internal gene (TRIG) constellation in 1998 with
surface proteins from human seasonal H3N2 (Zhou et al., 1999).
The introduction of human seasonal inﬂuenza viruses again in
2005 (Vincent et al., 2009), human seasonal N2 in 2002 (Nelson
et al., 2011, 2012b), and the spillover of the human 2009 pandemic
H1N1 (H1N1pdm09) virus (Nelson et al., 2012a; Pasma and Joseph,
2010; Pereda et al., 2010) have continued to add to the complex
IAV ecology in swine. As a result of these introductions, viral
reassortment, and antigenic drift, novel IAV continue to emerge in
swine, including reassortant H3N2-TRIG/H1N1pdm09 viruses that
recently caused multiple human infections (Ducatez et al., 2011;
Lindstrom et al., 2012). Currently, the H1α, H1β, H1γ, H1δ1, H1δ2,
H1N1pdm09 and H3 cluster IV (CIV) represent seven antigenically
distinct clusters co-circulating in U.S. swine (Lorusso et al., 2013;
Vincent et al., 2009). Consistent with the increasing antigenic
diversity recognized in swine-origin IAV is the lack of serological
cross-reactivity demonstrated between phylogenetic clusters in
hemagglutination inhibition (HI) tests (Lorusso et al., 2011).
Inﬂuenza vaccines are primarily used in adult female breeding
swine and during the grow/ﬁnish phase of production to decrease
IAV disease, lung lesions and transmission (Beaudoin et al., 2012;
Chen et al., 2012; Ma and Richt, 2010; Vincent et al., 2008b).
Protection against infection has relied on a systemic immune
response induced by whole inactivated virus (WIV) products, the
only preparation currently available for use in swine, in commer-
cial or autogenous vaccines delivered by the intramuscular route
(Van Reeth and Ma, 2013; Vincent et al., 2008b). The production of
“off-the-shelf” commercially available efﬁcacious WIV vaccines
has proven difﬁcult due to the number of valences required to
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minimize the antigenic distance between vaccine strains and
circulating IAV in swine (Gasparini et al., 2011). Current WIV
preparations used in swine include two or more representatives
of H1 and H3 cluster-types mixed with oil-based adjuvants,
however WIV vaccines have consistently been shown to provide
only partial protection against heterologous IAV infection and
shedding (Heinen et al., 2001; Kitikoon et al., 2006; Vincent
et al., 2008a, 2010a). Formulating and updating effective WIV
vaccines is additionally challenged by the difﬁculty in updating
vaccine seed viruses faster than the rate of signiﬁcant antigenic
evolution, the time needed to approve and license WIV products,
potential maternal antibody interference, and the lack of an
adequate mucosal and cell-mediated immune response (Kappes
et al., 2012; Kitikoon et al., 2006; Vincent et al., 2008b). Apart from
sub-optimal protection provided by WIV adjuvanted preparations
against mismatched circulating swine viruses in association with
the absence of cross-neutralizing antibodies, these vaccines may
be associated with vaccine-associated enhanced respiratory dis-
ease (VAERD) (Gauger et al., 2011, 2012; Kitikoon et al., 2006;
Vincent et al., 2008a). We have recently described the presence of
high titer cross-reacting antibodies targeting the conserved HA2
domain at a site adjacent to the fusion peptide (Khurana et al.,
2013). In the absence of neutralizing antibodies against the HA1
globular head of H1N1pdm09, we observed the HA2 antibodies
increased virus infection of MDCK cells in vitro and enhanced
membrane fusion (Khurana et al., 2013).
Alternative IAV vaccine platforms and methods of delivery are
needed to improve protection from heterologous infection and
reduce the risk of VAERD. Live attenuated inﬂuenza virus (LAIV)
vaccines administered by the mucosal route mimic natural infec-
tion and demonstrate the potential for broad cross-protective
immunity (Masic et al., 2009, 2010; Pena et al., 2011; Richt et al.,
2006; Vincent et al., 2007). In addition, LAIV vaccines may lack
some of the potential concerns posed by WIV products. Pigs
administered an intranasal H3N2 LAIV attenuated by truncation
of the NS1 protein in the presence of matching maternally derived
antibody (MDA) demonstrated better protection against challenge
with a heterologous H3N2 compared to pigs that received an
intramuscular WIV product (Vincent et al., 2012). Moreover, the
WIV vaccinated pigs in the same study developed VAERD that was
not observed in the LAIV group. This underscores another advan-
tage of using modiﬁed live vaccines in the context of antigenically
diverse IAV ecology observed in swine (Vincent et al., 2012). In
addition to the NS-1 truncated attenuation, inﬂuenza viruses
attenuated by modiﬁcations in the polymerase genes, rendering
the virus sensitive to physiologic temperatures, have been shown
to be efﬁcacious in swine (Pena et al., 2011).
The objective of the study reported here was to determine if
the use of a temperature sensitive LAIV would avoid or contribute
to VAERD in an H1 model that previously demonstrated VAERD in
pigs vaccinated with WIV (Gauger et al., 2011, 2012; Khurana et al.,
2013). Here, pigs were vaccinated with δ1H1N2 LAIV or WIV and
challenged with heterologous H1N1pdm09 virus. The two vaccine
platforms were compared to wild type virus exposure to evaluate
induction of humoral and cell-mediated immune responses in
various compartments. In addition to the traditional HI assay, we
measured antibody binding to the intact HA and to subdomains
HA1 and HA2 of the challenge virus (H1N1pdm09). Additionally, a
low challenge dose was administered to evaluate if VAERD was
dependent on the relatively higher dose used previously (Gauger
et al., 2011, 2012). These data demonstrate different outcomes of
heterologous challenge after LAIV compared with WIV vaccination
and suggest important differences in the type and speciﬁcity of
antibodies elicited by the vaccine platforms that provides further
insight into the conditions that lead to VAERD after hetero-
logous challenge.
Materials and methods
Viruses and vaccine preparation
Antigen for both vaccine platforms was a δ1 cluster H1N2
A/Sw/MN/02011/2008 (MN08) propagated in Madin-Darby canine
kidney (MDCK) cells. The LAIV vaccine was generated by introdu-
cing the MN08 HA and NA into the swine triple reassortant-
lineage A/turkey/Ohio/313053/04 H3N2 (OH04) attenuated back-
bone using reverse genetics (Pena et al., 2011). The OH04 isolate
was attenuated by modifying the polymerase genes creating a
temperature-sensitive strain as previously described in detail
(Pena et al., 2011). The LAIV was propagated at 35 1C on MDCK
cells. The WIV was prepared using UV irradiated MN08 with the
addition of a commercial oil-in-water adjuvant (Emulsigen D; MVP
Laboratories, Inc., Ralston, NE) at a v-v ratio of 4:1 virus to
adjuvant. Unaltered MN08 was used for the live virus exposure
designated as wild-type (WT) immune group. A sham vaccine (SV)
prepared using sterile MDCK cell culture supernatant diluted with
PBS was added 4:1 with adjuvant, consistent with the WIV
preparation. The challenge virus was prepared from A/California/
04/2009 H1N1 (H1N1pdm09) propagated in MDCK cells.
Experimental design
Ninety-six, three-week-old cross-bred pigs of mixed sex were
obtained from a herd free of IAV and porcine reproductive and
respiratory syndrome virus (PRRSV) and randomly divided into
four groups consisting of twenty-four pigs. Upon arrival, pigs were
housed in individual ABSL2 isolation rooms and treated prophy-
lactically with ceftiofur (Pﬁzer Animal Health, New York, NY)
according to label directions. Pigs were cared for in compliance
with the Institutional Animal Care and Use Committee of the
National Animal Disease Center.
Pigs received two doses of their respective vaccine at 4 and
7 weeks of age. Pigs in the LAIV- intranasal (LAIV-IN) group were
vaccinated with 2 ml of MN08 temperature sensitive LAIV at
1106 50% tissue culture infective dose (TCID50) per ml by slowly
dripping the vaccine alternately into both nostrils. Wild-type,
unaltered MN08 was administered at the same dose and by the
same method to pigs in the WT-IN immune group. The WIV-
intramuscular (WIV-IM) vaccinated pigs were administered
128 HA units of inactivated, adjuvanted vaccine by the intramus-
cular route. One group of twenty-four pigs received 2 ml of a sham
vaccine by the intramuscular route (SV-IM) and served as sham-
vaccinated controls.
Eight pigs in each IAV MN08 immune group and 8 SV-IM pigs
were euthanized at 0 dpi (pre-challenge) to collect bronchoalveo-
lar lavage ﬂuid (BALF) for antibody analysis in the lower respira-
tory tract. The remaining sixteen pigs in each IAV MN08 immune
group and 8 SV-IM pigs were challenged with a low dose (2 ml,
1103 TCID50/ml) of H1N1pdm09 by the intratracheal route at
10 weeks of age to compare efﬁcacies of the different vaccine
platforms. Eight of the SV-IM pigs remained non-challenge con-
trols (SV-NC) for the clinical evaluation and cytokine analysis. Pigs
were observed daily for clinical disease and rectal temperatures
were collected on - 1, 0, 1, 2, 3, 4 and 5 dpi. Nasal swabs (Fish-
erbrand Dacron swabs, Fisher Scientiﬁc, Pittsburg, PA) were taken
from all pigs on 0, 3 and 5 dpi to evaluate nasal virus shedding as
previously described (Vincent et al., 2012). Eight challenged pigs in
each immune group and 8 challenged SV-IM pigs were humanely
euthanized with a lethal dose of pentobarbital (Sleepaway, Fort
Dodge Animal Health, Fort Dodge, IA) at 5 dpi to evaluate les-
ions, viral replication and cytokine concentrations in the lungs.
Postmortem samples included serum, lung, trachea and BALF. The
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SV-NC pigs were euthanized on 21 dpi to evaluate cytokine
concentrations in BALF representing IAV-naïve pigs.
Diagnostic microbiology
Prior to the start of the study, all pigs were screened for
antibodies against inﬂuenza A nucleoprotein by ELISA (MultiS
ELISA, IDEXX, Westbrook, ME) to conﬁrm the absence of inﬂuenza
exposure. BALF samples were cultured for aerobic bacteria on
blood and Casmin (NAD enriched) agar plates and subjected to
nucleic acid extraction using the MagMax™ Viral RNA/DNA Isola-
tion Kit (Life Technologies, Carlsbad, CA) to detect potential
confounding respiratory pathogens. A polymerase chain reaction
(PCR) assay for PCV2 was conducted as previously described on
nucleic acid extracts from BALF collected at each necropsy
(Opriessnig et al., 2003). Commercial PCR assays for Mycoplasma
hyopneumoniae and PRRSV were conducted with the Applied
Biosystemss VetMaxTM M. hyopneumoniae reagents or the NA
and EU PRRSV-speciﬁc PCR assay (Life Technologies Carlsbad, CA),
respectively, according to manufacturer's recommendations
for serum.
Pathological examination of lungs
At 5 dpi, lungs were evaluated for macroscopic lesions consist-
ing of purple or red consolidation typical of IAV in swine. The
percent of the lung surface affected with consolidation was
subjectively estimated for each lung lobe and the total percentage
of pneumonia was calculated based on weighted proportions of
each lobe relative to the total lung volume as previously described
(Halbur et al., 1995). Microscopic lung and trachea lesions were
evaluated by a veterinary pathologist blinded to the treatment
groups after tissues were ﬁxed in 10% neutral buffered formalin,
embedded in parafﬁn and stained with hematoxylin and eosin.
Individual scores were assigned for each of six parameters as
previously described with modiﬁcations (Gauger et al., 2012). The
percentage of intrapulmonary airway epithelial necrosis or pro-
liferation was scored as follows: 0.0, no airway epithelial changes;
0.1–1.0, up to 25% of airways affected with bronchi or bronchiolar
epithelial damage; 1.1–2.0, 26–50% of airways affected; 2.1–3.0,
51–75% of airways affected; 3.1–4.0, 76–100% of airways affected
with intrapulmonary epithelial changes. The magnitude of peri-
bronchiolar lymphocytic cufﬁng was evaluated regardless of the
number of bronchi or bronchioles affected and were scored as
follows: 0.0, no discernible peribronchiolar cufﬁng observed; 1.0,
minimal, loosely formed cuffs; 2.0, mild, loosely to well-formed
cuffs; 3.0, moderate, well-formed or prominent lymphocytic cuffs;
4.0, severe, thick or densely-formed peribronchiolar cufﬁng. The
percentage of bronchi and bronchioles that demonstrated puru-
lent exudate (suppurative bronchitis or bronchiolitis) and propria
submucosa lymphohistiocytic inﬂammation were scored as fol-
lows: 0.0, no presence of neutrophils or inﬂammation; 0.1–1.0, up
to 25% of airways affected with inﬂammation; 1.1–2.0, 26–50% of
airways affected; 2.1–3.0, 51–75% of airways affected; 3.1–4.0,
76–100% of airways affected with neutrophils and marked propria
submucosa lymphohistiocytic inﬂammation. The presence and
severity of alveolar septal thickening with mononuclear inﬂam-
mation (interstitial pneumonia) was scored as follows: 0.0, no
interstitial pneumonia; 1.0, mild, focal to multifocal interstitial
inﬂammation; 2.0, moderate, locally extensive to multifocal inter-
stitial inﬂammation; 3.0, moderate, multifocal to coalescing inter-
stitial inﬂammation and alveolar septal thickening; 4.0, severe,
coalescing to diffuse interstitial thickening/inﬂammation. Two
additional subjective scores were based on the overall severity of
intrapulmonary epithelial exocytosis (microabscesses) in affected
airways and magnitude of alveolar and/or interlobular edema.
Epithelial exocytosis was scored as follows: 0.0, none; 1.0, 1–3
microabscesses; 2.0, 4–6 microabscesses; 3.0, more than 6 micro-
abscesses in the intrapulmonary epithelium. Edema was scored as
follows: 0.0, none; 1.0, mild, focal; 2.0, moderate, locally extensive;
3.0, severe, diffuse. A composite score was computed using the
sum of the 6 individual scores (range of 0–22). The average group
composite score was used for statistical analysis.
The trachea was evaluated with two individual scores based on
the magnitude of trachea epithelial attenuation or necrosis and
the degree of inﬂammation (tracheitis). Trachea epithelial scores
were deﬁned as follows: 0.0, normal epithelium over the entire
circumference; 1.0, mild epithelial changes (focal loss of cilia with
epithelial cell degeneration or ﬂattening); 2.0, mild epithelial
attenuation of approximately 2–3 cell layers either segmental or
multifocal (focal to multifocal loss of cilia and decreased number
of goblet cells); 3.0, moderate epithelial attenuation of approxi-
mately 1–2 cell layers, either segmental or multifocal (multifocal
loss of cilia and few goblet cells); 4.0, severe ﬂattened epithelium
with only a single layer of epithelium remaining, multifocal to
extensive (almost complete loss of all cilia and no goblet cells
remaining). Tracheitis scores were determined as follows: 0.0, no
inﬂammation; 1.0, minimal amount of suppurative or subepithelial
mononuclear inﬂammation; 2.0, mild, multifocal inﬂammation;
3.0, moderate, consistent inﬂammation affecting the trachea
epithelium or subepithelial space; 4.0, severe, coalescing to diffuse
inﬂammation of the epithelium or marked extension of inﬂamma-
tion into the subepithelial region. A composite score was com-
puted using the sum of the two individual trachea lesion scores
(range of 0–8). The average group composite score was used for
statistical analysis.
Serologic and mucosal antibody assays
Hemagglutination inhibition assays were conducted on serum
collected by anterior vena cava venipuncture from pigs in each
group at 0 dpi (day of challenge) with MN08 or H1N1pdm09 virus
as antigen and turkey red blood cells (RBC) as indicators using
standard techniques as previously described (Vincent et al., 2008a).
Reciprocal titers were divided by 10 and log2 transformed, analyzed,
and reported as the geometric mean.
Virus neutralization (VN) assays were conducted on BALF from the
thirty-two pigs euthanized at 0 dpi and serum neutralization (SN)
assays were conducted on serum from the thirty-two pigs challenged
at 0 dpi as previously described (Gauger et al., 2011; Loving et al.,
2012). Titers were recorded as the highest serum dilution negative for
CPE and negative for virus as veriﬁed by immunocytochemistry for all
plates. Reciprocal titers were divided by 10, log2 transformed, ana-
lyzed, and reported as the geometric mean.
Serum from twenty-four LAIV-IN, WT-IN and WIV-IM pigs pre-
challenge (0 dpi) were evaluated for binding to the H1N1pdm09
HA1 or HA2 domain in real-time kinetics using Surface Plasmon
Resonance (SPR). A ProteOn SPR biosensor (Bio-Rad) was used to
monitor steady-state equilibrium binding of individual pig sera
(Khurana et al., 2011b, 2013). Antibody binding is expressed as
maximum RU (max RU) values.
Enzyme-linked immunosorbent assays (ELISA) to detect total
IgG and IgA antibodies against whole virus preparations of MN08
and H1N1pdm09 present in serum and BALF from all pigs at 0 dpi
were performed as previously described with modiﬁcations
(Gauger et al., 2011). Sera were heat inactivated at 56 1C for
30 min and diluted in 5% Fraction V bovine serum albumin (BSA)
(Life Technologies/Gibco, Grand Island, NY) in phosphate buffered
saline (PBS) at 1:2000 and 1:4 for IgG and IgA assays, respectively,
to adsorb non-speciﬁc binding. The BALF samples were incubated
at 37 1C for 1 h with an equal volume of 10 mM dithiothreitol
(DTT) to disrupt mucus prior to dilution with an equal volume of
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10% BSA-PBS resulting in a ﬁnal BALF dilution of 1:4. The BSA
treated sera and BALF were incubated at 37 1C for 1 h immediately
prior to testing.
Concentrated MN08 and H1N1pdm09 were resuspended in
Tris-EDTA basic buffer, pH 7.8, and diluted to an HA concentration
of 100 HA units/50 μl. Immulon-2HB 96-well plates (Dynex, Chan-
tilly, VA) were coated with 50 μl of either antigen and incubated at
room temperature overnight. Plates were blocked for 1 h at room
temperature with 150 μl of Starting Block (Thermo Fisher Scien-
tiﬁc, Pittsburgh, PA) and washed 3 times with 200 μl of 0.05%
Tween 20 in PBS (PBS-T). Independent assays were performed
with each antigen using 50 μl of diluted sera or BALF in duplicate.
Plates were incubated at room temperature for 1 h and washed
3 times with PBS-T. Fifty microliters of peroxidase-labeled goat
anti-swine IgG (Kirkegaard & Perry Laboratories, Gaithersburg,
MD) or anti-swine IgA (Bethyl, Montgomery, TX) diluted 1:1500 in
Starting Block was added to each well for 1 h at room temperature.
Plates were washed 3 times with PBS-T prior to adding 50 μl of 2,
20-azino-di(3-ethylbenzthiazoline-6-sulfonate) (ABTS)-peroxide as
the substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD)
for 8–10 minutes and the subsequent addition of 50 μl KPL Stop
Solution (Kirkegaard & Perry Laboratories, Gaithersburg, MD). The
optical density (OD) was measured at 405 nm wavelength with an
automated ELISA reader. Antibody levels were reported as the
mean OD for each duplicate sample, and the mean OD of each
treatment group was compared.
Virus infection assay in MDCK cells
Sera from individual LAIV-IN, WT-IN and WIV-IM vaccinated
pigs pre-challenge (0 dpi) were analyzed in an H1N1pdm09 virus
infection assay as previously described (Khurana et al., 2011a,
2013). A nucleoprotein-based ELISA was used to determine the
virus titer expressed as a percent of control infection. Sera from
H1N1pdm09 WIV-vaccinated animals were added as positive
controls. The inhibition curve with these sera was not altered in
the presence of pre-vaccination sera (Khurana et al., 2013).
Lung cytokine assays
BALF samples collected from twenty-four pre-challenge pigs at
0 dpi, twenty-four challenged pigs at 5 dpi and 8 SV-NC pigs at
21 dpi were centrifuged at 400 x g for 15 min at 4 1C to pellet
cellular debris. Cytokine concentrations in cell-free BALF, which
included IL-1β, IL-2, IL-6, IL-8, IL-12p70, IL-10, TNFα and IFNγ,
were determined by multiplex ELISA performed according to the
manufacturer's recommendations (SearchLight, Aushon Biosys-
tems, Billerica, MA). Cytokine concentrations were reported as
the mean of duplicate samples for statistical analysis.
Statistical analysis
Macroscopic and microscopic pneumonia scores, log2 trans-
formed HI and SN reciprocal titers, log10 transformed nasal swab
and BALF virus titers, mean OD ELISA IgG and IgA antibody levels,
maximum RU HA1 and HA2 binding data, percent virus infection in
the MDCK cell-based assay and cytokine concentrations were
analyzed using analysis of variance (ANOVA) with a P-valueo0.05
considered signiﬁcant (JMP, SAS Institute, Cary, NC; GraphPad Prism
Version 5.00, San Diego, CA). Response variables shown to have a
signiﬁcant effect by treatment group were subjected to pair-wise
mean comparisons using the Tukey–Kramer test or a Dunnet's
multiple comparison test for cytokine concentrations. Group means
with statistical difference are indicated by connecting bars. Rectal
temperature data were analyzed using a mixed linear model for
repeated measures using SAS 9.1 for Windows (SAS Institute, Cary,
NC, USA). Linear combinations of the least squares means estimates
were used in a priori contrasts after testing for a signiﬁcant
(Po0.05) treatment group effect of vaccination status. Comparisons
were made between each group at each time-point using a 5% level
of signiﬁcance (Po0.05) to assess statistical differences.
Results
Clinical disease
Clinical signs consistent with IAV respiratory disease in swine
were more severe over a prolonged period of time in the WIV-IM
pigs compared to all other vaccinated and challenged immune
groups and compatible with current descriptions of VAERD
(Gauger et al., 2011, 2012). All WIV-IM pigs demonstrated cough-
ing or respiratory distress at various times post-challenge and an
average of 63% (10 of 16) of the WIV-IM pigs demonstrated IAV
clinical signs from 1 to 5 dpi. In contrast, mild, transient lethargy
and anorexia and mild coughing was occasionally observed in
some of the pigs in the LAIV-IN or WT-IN vaccinated groups at
24 h post infection.
All MN08 vaccinated and sham-vaccinated immune groups
challenged with H1N1pdm09 demonstrated mean febrile responses
at 1 dpi deﬁned as two standard deviations above the mean rectal
temperature prior to challenge (Z39.9 1C) that were signiﬁcantly
higher than the SV-NC group (Supplemental Fig. S1). However, the
LAIV-IN and WT-IN mean rectal temperatures were signiﬁcantly
lower than the SV-IM challenge control group at 1 dpi. By 2 dpi,
LAIV-IN, WT-IN and SV-IM mean rectal temperatures were not
different than the non-challenged controls and signiﬁcantly lower
than the WIV-IM group. In addition, WIV-IM pigs demonstrated
signiﬁcantly elevated rectal temperatures at 3 and 4 dpi compared
to all other immune groups and remained signiﬁcantly higher at
5 dpi compared to the LAIV-IN, WT-IN, and SV-NC groups. These
data are consistent with the prolonged elevated body temperatures
described in VAERD-affected swine (Gauger et al., 2011).
Viral and microbiological assays
Inﬂuenza A virus antibodies were not detected in pigs prior to
vaccination and virus was not detected pre-vaccination, one week
post boost, or at 0 dpi. Extraneous viral or M. hyopneumoniae
nucleic acids were not detected in BALF collected from pigs
necropsied at 5 dpi. Aerobic bacterial cultures yielded no signiﬁ-
cant growth of respiratory pathogens, thus the severe lung
pathology described in WIV-IM, VAERD-affected pigs was not
associated with bacterial pneumonia.
Lung and trachea pathology and replication of challenge virus
Pigs administered the WIV-IM vaccine and challenged with a
low dose of H1N1pdm09 demonstrated enhanced macroscopic
lung lesions (Fig. 1A) with an average of 25% macroscopic pneu-
monia, signiﬁcantly higher compared to the mean lung consolida-
tion demonstrated by the SV-IM pigs (Fig. 1B). Pigs that received
the WT virus (Fig. 1C) or LAIV (Fig. 1D) intranasal vaccines
demonstrated mild pneumonia, averaging 3.7 and 1.7 percent of
the lung, respectively, that were similar to the percent pneumonia
observed in the SV-IM pigs, and signiﬁcantly lower compared to
the WIV-IM immune group (Fig. 1E). Importantly, enhanced
macroscopic lung pathology was not recognized in the LAIV
vaccinated pigs in spite of the heterologous challenge.
Challenge virus was detected in nasal secretions in 1/8 SV-IM pigs
and 4/8 pigs in the WIV-IM group at 3 dpi, likely inﬂuenced by the
low challenge dose. However, by 5 dpi, virus was isolated from nasal
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secretions of 8/8 pigs in the SV-IM group and 3/8 pigs in theWIV- IM
group. Mean nasal virus titers at 3 dpi were signiﬁcantly higher in
the WIV-IM group compared to LAIV-IN and WT-IN pigs (Fig. 1F). In
contrast, 5 dpi nasal virus titers were signiﬁcantly higher in the SV-
IM pigs compared to all other immune groups (Fig. 1F). Virus titers
decreased between 3 and 5 dpi in the WIV-IM pigs in contrast to the
SV-IM group that demonstrated higher titers by 5 dpi and higher
numbers of individual pigs shedding virus. Importantly, no challenge
virus was detected in nasal secretions from pigs immunized with
LAIV-IN or WT-IN, suggesting adequate cross-protection against
H1N1pdm09 by prior live or live-attenuated virus immunity
(Fig. 1F). Virus was detected only in the SV-IM and WIV-IM BALF at
necropsy (5 dpi) (Fig. 1F). Although less than SV-IM challenge
controls, pigs administered the WIV-IM vaccine had signiﬁcantly
higher virus titers compared the LAIV-IN andWT-IN immune groups,
which had no virus isolated from BALF. These ﬁndings suggest the
VAERD-affected pigs demonstrated accelerated virus replication in
the upper respiratory tract compared to the LAIV-IN and WT-IN
groups. It is possible that by 5 dpi at the peak of airway epithelial
damage, the infection was self-limiting due to lack of target cells
compared to the SV-IM control group.
Microscopic lung lesion scores followed a similar trend as the
magnitude of lung consolidation. The WIV-IM vaccine failed to
protect pigs from infection or disease and resulted in lung lesions
Fig. 1. Macroscopic lung lesions from representative pigs in H1N1pdm09 challenged immune groups. Pigs in the WIV-IM (A) group demonstrating VAERD had a signiﬁcantly
higher mean percentage of lung consolidation compared to all other groups. The SV-IM (B), WT-IN (C) and LAIV-IN (D) pigs demonstrated mild lung consolidation although
group mean percentage of pneumonia was not statistically different from each other (E). H1N1pdm09 titers in nasal swab and bronchoalveolar lavage at 3 and 5 dpi (F). Data
are expressed as the mean percent pneumonia or mean log10 virus titer7standard error of the mean of each group. Connecting lines are signiﬁcantly different at Po0.05.
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characterized as severe necrotizing bronchiolitis with marked
peribronchiolar lymphocytic cufﬁng and interstitial pneumonia.
Lesions were similar to what has been previously described for
VAERD (Gauger et al., 2012) including a characteristic suppurative
bronchiolitis and alveolitis with hemorrhage and edema and
extensive mononuclear inﬂammation of the propria submucosa
(Fig. 2A). Composite microscopic lung lesion scores were signiﬁ-
cantly higher in the WIV-IM pigs compared to all other immune
groups (Fig. 2F). Signiﬁcant differences were not recognized in
microscopic lung lesion scores between the SV-IM (Fig. 2B) and
WT-IN immune groups (Fig. 2C). However, the LAIV-IM (Fig. 2D)
pigs demonstrated the least amount of microscopic lung inﬂam-
mation compared to all immune/challenged groups and were
signiﬁcantly lower than the WIV-IM and SV-IM microscopic lung
lesion scores. These data suggest the LAIV vaccine induced partial
cross-protection that was associated with an absence of VAERD
unlike the WIV vaccinated/challenged pigs.
In addition to pathologic changes in lungs, the trachea in VAERD-
affected pigs (WIV-IM) was characterized by severe epithelial attenua-
tion or necrosis (Fig. 2E) that occasionally resulted in a single layer of
epithelium. The submucosa was inﬁltrated with large numbers of
lymphocytes, neutrophils and to a lesser extent with macrophages
(Fig. 2E). Neutrophils had often transmigrated the tracheal epithelium
or formedmicroabscesses that were rarely observed in LAIV-IN,WT-IN
or non-vaccinated pigs. The WIV-IM trachea lesion composite scores
were signiﬁcantly higher compared to all other immune groups (data
not shown). Trachea lesion scores were not statistically different
between the SV-IM pigs and the LAIV-IN and WT-IN immune groups.
However, a trend for lower trachea composite scores was observed in
the pigs that were immunized with the intranasal wild type or
attenuated viruses.
Serology
Homologous HI titers detected the day of challenge (0 dpi)
were signiﬁcantly higher in the WIV vaccinated pigs compared to
all other immune groups with a geometric mean reciprocal titer of
415 (Fig. 3A). The intranasally administered LAIV and WT MN08
virus induced lower geometric mean HI titers of 104 and 113,
respectively, although all pigs in those immune groups had HI
Fig. 2. Microscopic lung lesions from representative pigs in H1N1pdm09 challenged immune groups. Pigs in the WIV-IM group demonstrating VAERD (A) had marked
peribronchiolar cufﬁng (double arrow) and increased inﬂammation of the propria submucosa (arrowhead) with marked interstitial pneumonia. Pigs in the SV-IM (B), WT-IN
(C) and LAIV-IN (D) groups demonstrated similar lung lesions consisting of mild peribronchiolar cufﬁng (arrowhead) and interstitial pneumonia. VAERD-affected pigs also
demonstrate severe necrosis (arrow) and sloughing (asterisk) of the tracheal epithelium with marked submucosal inﬂammation (arrowhead) (E). (Lung, 200X; Trachea,
400X). WIV-IM mean microscopic pneumonia scores (F) were signiﬁcantly higher compared to all other immune groups. Data are expressed as the mean composite
score7standard error of the mean of each group. Connecting lines are signiﬁcantly different at Po0.05.
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titers of 40 or higher. All immune groups had HI titers signiﬁcantly
higher compared to the SV-IM pigs. Cross-reactive heterologous HI
titers to the H1N1pdm09 challenge virus were not detected at
0 dpi in any pigs regardless of HI titer to MN08.
Homologous serum neutralizing (SN) antibody titers were
detected at high levels in all MN08-immune pigs prior to challenge
(Fig. 3B). Signiﬁcant differences were not detected between WIV-
IM and WT-IN immune group SN titers, and both were signiﬁ-
cantly higher than the LAIV-IN SN titer. Cross-reactive anti-
H1N1pdm09 SN antibodies were not detected in any of the
MN08 immune groups at 0 dpi. The SV-IM pigs were HI and SN
antibody negative against both antigens prior to challenge.
To further explore the type of antibodies elicited by the
different vaccine modalities we used whole-virus ELISA to mea-
sure binding of pre-challenge IgG antibodies in sera to the priming
(MN08) and challenge (H1N1pdm09) virions, respectively (Fig. 3C
and D). The highest homologous virus binding antibodies were
detected in the WIV-IM group followed by the WT-IN and then the
LAIV-IN vaccinated pigs (Fig. 3C). Importantly, binding to the
heterologous H1N1pdm09 challenge virus was prominent in the
WIV-IM pigs, but minimal in the WT-IN or LAIV-IN immune
groups that demonstrated binding levels similar to SV-IM (unvac-
cinated) control animals (Fig. 3D). This ﬁnding was very striking
based on the low amino acid similarity of the HA and NA between
MN08 and H1N1pdm09 (78% for HA and 43% for NA).
Serum antibody binding to HA1 and HA2 of H1N1pdm09
We further explored the speciﬁcity of the heterologous virus
antibody binding using recombinant HA1 (aa 1–320) and HA2 proteins
from the H1N1pdm09 that were expressed in a bacterial system and
shown to be properly folded. These HA domains were coated onto SPR
chips as previously described (Khurana et al., 2013). Sera from all
immune groups displayed low and similar mean levels of anti-HA1
H1N1pdm09 antibodies (max RU) (Fig. 3E). This low level of cross-
reactive antibodies against the HA1 domain of H1N1pdm09 was
Fig. 3. Serum antibody responses in pigs vaccinated with LAIV, WT, WIV or SV prior to challenge (0 dpi). Hemagglutination inhibition (A) and serum neutralization
(B) geometric mean reciprocal titers to homologous vaccine virus were signiﬁcantly higher in the WIV-IM pigs compared to all immune groups. Cross-reactive HI or SN
antibodies against H1N1pdm09 were not detected. Whole virus MN08 (C) and cross-reactive H1N1pdm09 (D) serum IgG levels detected in WIV-IM pigs were signiﬁcantly
higher than LAIV, WT or SV pigs. Anti-HA1 H1N1pdm09 serum antibody levels (E) were similar in LAIV, WT and WIV vaccinated pigs. Serum from WIV-IM vaccinates
demonstrated preferential binding to the HA2 domain of H1N1pdm09 (F). Data are expressed as the geometric mean titer or mean optical density/max RU7the standard
error of the mean of each group. Connecting lines are signiﬁcantly different at Po0.05.
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consistent with the lack of detectable HI or SN serum antibodies
against the challenge virus. However, WIV-IM vaccinated pig sera at
0 dpi demonstrated signiﬁcantly higher cross-reactive binding against
the H1N1pdm09 HA2 domain compared to sera from LAIV-IN or WT-
IN vaccinated pigs (Fig. 3F). Elevated cross-reactive HA2-targeting
antibodies were reported in our earlier paper describing the mechan-
ism of VAERD (Khurana et al., 2013) and is consistent with the higher
serum antibody binding observed in WIV-IM vaccinated animals to
the H1N1pdm09 whole virus (Fig. 3F vs. 3D). The homology between
the HA2 domains of MN08 and H1N1pdm09 is approximately 89%
(signiﬁcantly higher than for the entire HA), yet very minimal HA2-
binding activity was found in the sera of animals primed with either
WT-IN or LAIV-IN.
Serum H1N1pdm09 infectivity assay
In order to link the observed H1N1pdm09 HA1/HA2 total binding
with the function of the MN08 vaccine induced antibodies, we
evaluated these sera in the MDCK-based microneutralization assay
(based on the CDC recommended protocol) using H1N1pdm09 virus
(Khurana et al., 2011a). Archived sera from H1N1pdm09 WIV-
vaccinated animals demonstrated the expected efﬁcient neutralization
of H1N1pdm09 in the MDCK assay (Fig. 4, green curves). However,
sera from the MN08 WIV-IM vaccinated animals from this study did
not inhibit, but rather increased H1N1pdm09 infection in MDCK cells
in a concentration-dependent manner (180–220% of virus-only control
cultures at the lowest dilution) (Fig. 4A). Addition of pre-vaccination
sera did not change the neutralization dilution curves for the
H1N1pdm09 immune sera similar to what was described in the
earlier study (Khurana et al., 2013). In contrast, sera from WT-IN
(Fig. 4B) or LAIV-IN (Fig. 4C) vaccinated pigs did not enhance virus
infection of MDCK cells compared to virus only control. Together these
data demonstrated that vaccination with MN08 WIV-IM elicited high
titer cross reactive antibodies preferentially targeting the HA2 stalk of
the heterologous H1N1pdm09 challenge virus, resulting in fusion/
infection enhancement in vitro and likely in vivo during early time
points post-infection, in the absence of HA1-targeting antibodies
(3 dpi, Fig. 1F). In contrast, the LAIV-IN vaccine modality did not
induce infection-enhancing antibodies, had reduced virus titers in vivo
at 3 dpi (and all time points), and did not lead to VAERD after
heterologous challenge (Figs. 1–2).
Mucosal antibody responses
LAIV-IN and WT-IN pigs demonstrated VN antibodies against
the homologous MN08 virus in the BALF prior to challenge (0 dpi),
but not against the heterologous H1N1pdm09 challenge virus.
MN08 or H1N1pdm09 VN antibodies were not detected in the
BALF fromWIV-IM pigs (data not shown). Anti-MN08 (Fig. 5A) and
–H1N1pdm09 (Fig. 5B) IgG antibody responses in the lower
respiratory tract were detected at 0 dpi in all MN08 immunized
pigs regardless of the vaccine type or route of delivery. There were
signiﬁcant levels of anti-MN08 IgG in the BALF from LAIV and WT
vaccinated pigs compared to the WIV-IM group; however, cross-
reactive anti-H1N1pdm09 IgG levels were similar among all
vaccine groups. Anti-MN08 (Fig. 5C) and –H1N1pdm09 (Fig. 5D)
IgA antibodies in the BALF at 0 dpi were signiﬁcantly higher in pigs
that received intranasal immunization compared to the WIV-IM
and SV-IM groups. Anti-MN08 and –H1N1pdm09 IgA antibody
levels in WIV-IM vaccinates were detected at baseline levels
similar to the non-vaccinated SV-IM group.
Cytokine concentrations in BALF
Three weeks after the booster dose of vaccines or WT exposure
and just prior to challenge, pro-inﬂammatory cytokine levels in the
lung were at baseline levels in all vaccinated groups (data not
shown). However, at 5 dpi, the WIV-IM vaccinated, VAERD-affected
group demonstrated signiﬁcantly elevated concentrations of IL-1β,
TNF-α and IL-6 compared to pre-challenge baseline levels and
compared to the SV-IM and intranasal vaccinated pigs as well as
non-challenged pigs (SV-NC) (Fig. 6A). Levels of cytokines associated
with adaptive immunity were evaluated as an indirect measure of
T-cell activity. Concentrations of IFN-γ, IL-2 and IL-12p70 were also
higher in the WIV-IM group over all other immune groups and
sham-vaccinated pigs (Fig. 6B). These increased levels of cytokines
were concurrent with the inﬂux of lymphocytes, macrophages, and
neutrophils and the tissue damage in VAERD lungs, observed as
early as 1 day (Gauger et al., 2012) and peaking at 5 days post
H1N1pdm09 infection (Fig. 2).
Fig. 4. Virus infection assay in Madin–Darby canine kidney cells detected by a
nucleoprotein-based ELISA. WIV-IM vaccinated pig sera enhanced H1N1pdm09
infectivity in MDCK cells (A). Sera from WT-IN (B) and LAIV (C) vaccinated pigs did
not demonstrate H1N1pdm09 virus infectivity that was different from virus control
sera. Control sera from H1N1pdm09 immunized pigs demonstrate a dose depend
neutralization of H1N1pdm09 virus. Data are expressed as a percent of control
infection.
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Fig. 5. Antibody responses in bronchoalveolar lavage from pigs vaccinated with LAIV, WT, WIV or SV at 0 dpi. LAIV-IN and WT-IN homologous (A) IgG were signiﬁcantly
higher compared to WIV-IM vaccinated pigs. However, cross-reactive (B) IgG were detected at similar levels regardless of vaccine. Homologous (C) and cross-reactive (D) IgA
antibodies were signiﬁcantly higher in pigs that received intranasal vaccination compared to WIV-IM and SV vaccinates. Data are expressed as the mean optical
density7standard error of the mean. Connecting lines are signiﬁcantly different at Po0.05.
Fig. 6. Lung pro-inﬂammatory cytokine concentrations from H1N1pdm09 challenged and non-challenged immune groups. Post-challenge TNF-α, IL-1β and IL-6 protein
concentrations in bronchoalveolar lavage ﬂuid were signiﬁcantly higher in pigs administered the WIV-IM vaccine and demonstrating VAERD compared to other vaccinated/
challenged groups (A). Signiﬁcant differences between cytokine levels were not observed between SV-IM, WT-IN and LAIV-IN groups. Post-challenge IFN-γ, IL-2 and IL-12p70
protein concentrations in bronchoalveolar lavage ﬂuid were signiﬁcantly higher in pigs administered the WIV-IM vaccine and demonstrating VAERD compared to other
vaccinated/challenged groups (B). Signiﬁcant differences between cytokine levels were not observed between SV-IM, WT-IN and LAIV-IN groups. A vaccinated/non-
challenged (SV-NC) group euthanized at 21 dpi was included in the cytokine evaluation as a non-infected control. Data presented as box and dot plots with the mean
cytokine concentration (pg/ml)7standard error of the mean. Signiﬁcantly different cytokine concentrations between the WIV-IM and SV-IM group are identiﬁed by
connecting lines at Po0.05 with some data not shown. SV-IM, sham vaccinated/intramuscular vaccine; LAIV-IN, live attenuated inﬂuenza virus/intranasal vaccine; WT-IN,
wild type virus/intranasal exposure; WIV-IM, whole inactivated virus/intramuscular vaccine; SV/NC, non-vaccinated/non-challenged.
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Discussion
WIV inﬂuenza vaccines are used frequently in swine in the US
and rely on the induction of a systemic immune response to
protect the respiratory tract against inﬂuenza infection (Ma and
Richt, 2010; Vincent et al., 2008b). WIV preparations described in
previous reports have demonstrated adequate protection against
homologous challenge or heterologous viruses with cross-reactive
HI activity. However, efﬁcacy against heterologous IAV is often
deﬁcient (Bikour et al., 1996; Lee et al., 2007; Van Reeth et al.,
2004; Vincent et al., 2008a), similar to the situation with human
seasonal vaccines. In addition, enhanced respiratory disease has
been observed in several cases where heterologous infection
occurred after vaccination with mismatched WIV vaccines
(Gauger et al., 2011, 2012). Our recent publication suggested that
the balance between protective antibodies primarily targeting the
globular head domain and stalk-targeting antibodies against the
conserved HA2 may play a role in infection outcome (Khurana et
al., 2013). Among the cross-reactive HA2 antibodies, there may be
some protective or possibly broadly neutralizing antibodies as
recently described (Gocnik et al., 2008; Hashem et al., 2010).
However, in the VAERD pig model, we have identiﬁed polyclonal
cross-reactive HA2-targeting antibodies that may attach to virions
and enter the endocytic compartment where they promote rather
than block the fusion process (Gauger et al., 2011; Khurana et al.,
2013).
It was not clear if these enhancing antibodies were more likely
to be generated by WIV vaccines or irrespective of the vaccine
platform. Furthermore, the increasing antigenic diversity of con-
temporary IAV circulating in North American swine increases the
need for improved vaccines and methods of delivery that could
provide sufﬁcient cross-protection against heterologous infections.
Improved vaccines could decrease viral transmission among pigs
reducing the likelihood of reassortment that often results in newly
emerging strains that may also jump to humans (Garten et al.,
2009; Nelson et al., 2012b; Shu et al., 2012). Live attenuated
inﬂuenza vaccines with genetic modiﬁcations through targeted
mutations have demonstrated more consistent cross-protection
and reduction in shedding compared to WIV products (Pena et al.,
2011; Vincent et al., 2007).
The current study demonstrated that swine administered a
temperature sensitive LAIV vaccine exhibited mitigated clinical
signs, fewer macroscopic and microscopic lung lesions compared
to the WIV-IM and unvaccinated (SV) animals and protection
against infection and replication in the upper respiratory tract
following challenge with a heterologous IAV (Figs. 1 and 2).
Although the average lung consolidation described in the positive
control SV-IM H1N1pdm09-challenged pigs was lower than what
was previously reported (Vincent et al., 2010b), there was a trend
for reduced macroscopic pneumonia in the LAIV-IN and
WT-IN pigs. The lower challenge dose of virus in this study likely
contributed to the reduced or delayed magnitude of lung lesions
observed in pigs infected with H1N1pdm09. Most importantly,
enhanced respiratory disease was only observed in WIV-IM vacci-
nated animals but not in pigs that received the intranasal LAIV
vaccine, suggesting a decreased risk of VAERD after mismatched
vaccination. The magnitude of protection described in the LAIV
group was similar to pigs administered the wild type MN08
(WT-IN), indicating the attenuated virus evaluated here paralleled
the cross-protection by natural infection in this study and as previ-
ously described (Van Reeth et al., 2003). Since no cross-reactive
H1N1pdm09 serum neutralizing antibodies were measured in any
vaccine group, other mechanisms of protection could be postulated,
including cell mediated immunity against conserved internal genes.
Whole virus, cross-reactive IgG antibodies were only detected in
sera from WIV-IM vaccinated animals. Further analysis revealed
these WIV-IM serum antibodies preferentially bound to the con-
served HA2 domain of H1N1pdm09 and increased in vitro infectiv-
ity of MDCK cells as previously reported (Khurana et al., 2013). In
both studies, the HA2 targeting antibodies and antibody-mediated
enhanced MDCK cell-infectivity correlated with increased lung
pathology. In addition, the enhanced MDCK cell-infectivity demon-
strated in the WIV-IM pig sera (Fig. 4A) is consistent with the
elevated virus titers detected at 3 dpi in nasal swabs in the VAERD-
affected pigs. In contrast, cross-reactive anti-HA1 or –HA2 anti-
bodies were detected at minimal levels in serum from LAIV-IN or
WT-IN, with no evidence of preferential binding to HA2. Therefore,
when challenged with mismatched virus, pigs lacking protective
antibodies in the presence of high titer anti-HA2 antibodies that
target a critical site on the HA2 stem (close to the fusion peptide)
may have an increased risk of VAERD. Future studies should
evaluate potential differences in the type of antibodies elicited by
inactivated vaccines with different adjuvants and replicating virus
vectors.
Intranasal LAIV vaccines have the advantage over inactivated
products of inducing local IgA that has been correlated with cross-
protection against heterologous challenge (Loving et al., 2013;
Vincent et al., 2007, 2012). The temperature sensitive LAIV vaccine
used in this study demonstrated a cross-reactive H1N1pdm09
speciﬁc IgG antibody response to whole virus in the BALF at 0 dpi
that was similar to levels demonstrated by the WIV pigs (Fig. 5B).
However, signiﬁcantly higher levels of homologous and cross-
reactive (anti-H1N1pdm09), whole virus IgA were detected in the
lower respiratory tract of LAIV-IN and WT-IN vaccinates compared
to the WIV-IM, VAERD-affected group prior to challenge (Fig. 5C
and D). The mild post-challenge clinical signs and lung lesions
demonstrated by the LAIV immune group in the absence of anti-
H1N1pdm09 serum neutralizing antibodies suggests a role for
cross-reactive mucosal IgA in protection from infection and clinical
disease. Although 0 dpi BALF neutralizing antibodies were not
detected against heterologous virus in the VN assay, the cross-
reactive IgA detected in BALF from the LAIV-IN group still may
have been associated with the absence of VAERD and reduced
infection. This effect could be through differential processing of
antigen bound by IgA versus IgG or through interference with
virus infection since polymeric IgA is more cross-reactive than IgG
(Asahi et al., 2002; Tamura et al., 1991). On the other hand, the
level of BALF IgG antibodies was not signiﬁcantly different
between the three vaccine groups. Therefore, any protective role
associated with IgA antibodies may be offset by IgG antibodies
with no or opposing biological activities. Due to limited volumes, it
was not possible to determine the antigen's epitopes targeted by
the BALF antibodies. Regardless of the underlying mechanism
(antibody or CMI), mucosal vaccination and local IgA may be
crucial to the reduction in viral replication and nasal shedding in
the upper and lower respiratory tract.
Elevated pulmonary pro-inﬂammatory cytokines are a consistent
feature of the VAERD phenomenon in swine and may contribute to
excessive inﬂammation or lung damage (Gauger et al., 2011; Gauger
et al., 2012; Van Reeth et al., 2002). Post-challenge cytokine con-
centrations in the BALF were highly variable in all experimental
groups in the present study. Still, signiﬁcantly higher group mean
cytokine levels of TNF-α, IL-1β and IL-6 were only observed in the
WIV-IM, VAERD-affected pigs compared to the sham-vaccinated and
LAIV (or WT) vaccinated groups (Fig. 6) that also demonstrated
minimal lung lesions (Figs. 1E & 2F), further suggesting an association
of aberrant cytokine responses with the incidence of VAERD. The
proinﬂammatory cytokines measured in the BALF of animals with
VAERD at day 5 post-challenge may have been produced by an inﬂux
of inﬂammatory “activated” macrophages, dendritic cells, and neu-
trophils responding to the initial tissue damage by enhanced fusion/
virus replication in the epithelial cells. This may have ultimately
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limited the level of viral replication observed at 5 dpi in lung and the
upper respiratory tract. MDCK cells are epithelial cells and do not
express Fc receptors. Therefore, Fc-mediated antibody enhancement
is not implicated by increased virus infectivity in vitro, whereas
increased virus fusion in the presence of antibody from WIV
vaccinated pigs in epithelial cells is a potential mechanism as
previously demonstrated (Khurana et al., 2013). However, a possible
role for Fc receptor mediated uptake of antibody bound virus and
VAERD-associated aberrant lung cytokine responses in vivo requires
further investigation.
The results of this study demonstrate critical advantages to the
use of LAIV vaccines in swine populations where a diverse IAV
ecology has been established. Intranasal LAIV vaccines have the
ability to induce a broad, cross-protective immune response
similar to natural infection that may include priming of cell-
mediated immunity and protective local immunity without the
risk of VAERD. A source of resistance to the use of LAIV in swine is
a potential reversion to virulence and reassortment between wild-
type and vaccine strains. Reversion to virulence has never been
conﬁrmed in human LAIV products and the temperature sensitive
platform used in this report has multiple attenuating mutations,
reducing the opportunity for reversion. Additionally, the LAIV used
here is from the North American swine-lineage, contributing no
extraneous genetic material if reassortment occurred. LAIV vac-
cines have consistently been shown to signiﬁcantly reduce viral
replication and shedding which, if performance were mimicked in
the ﬁeld, LAIV would greatly decrease virus transmission, reduce
the emergence of divergent IAV, and potentially reduce zoonotic
events such as those that recently occurred in the human popula-
tion (Bowman et al., 2012; Killian et al., 2013; Wong et al., 2012).
These beneﬁts outweigh concerns delaying the progress of licen-
sing LAIV for use in the swine population.
Conclusions
Inactivated inﬂuenza vaccines are commonly used in United States
swine increasing the opportunity of mismatched vaccination against
antigenically diverse viruses circulating in swine. This study demon-
strates that vaccination with WIV, but not LAIV or WT, elicited cross-
reactive HA-2 targeting antibodies that in the absence of anti-HA1
neutralizing antibodies may have been associated with enhan-
ced respiratory disease after challenge with the mismatched H1N1
virus in the pig model. These data suggest live attenuated vaccines
administered in the upper respiratory tract may induce broad cross-
protection, reduce the risk of enhanced disease, and could serve as an
alternative to whole inactivated virus vaccines in swine.
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